氯胺酮抑制急性脑损伤中的扩散性去极化:一项前瞻性、随机、多交叉试验
该试点试验纳入10例重型创伤性脑损伤或动脉瘤性蛛网膜下腔出血患者,在开颅时放置标准皮层脑电条,随机交替每6小时接受氯胺酮或其他镇静剂,发现氯胺酮在常用镇静剂量范围内呈剂量依赖性抑制扩散性去极化。
要点
- 氯胺酮在常用镇静剂量范围内有效抑制扩散性去极化(SD)。
- 停用氯胺酮或剂量低于1.15 mg/kg/hr时SD风险增加(OR 13.838)。
- 所有氯胺酮数据合并后,用药期间SD减少趋势未达统计学显著(χ2=3.86,p=0.42)。
核心结论
- 氯胺酮在常用镇静剂量范围内有效抑制SD,即使在非插管患者中亦如此。
- 这些数据首次前瞻性证明SD的发生可受临床干预影响,而非仅仅是损伤后不可避免的伴随现象。
- 这些数据为未来评估SD导向治疗临床改善的研究提供了基础。
研究设计与样本
- 前瞻性、随机、多交叉试点试验,纳入10例重型创伤性脑损伤或动脉瘤性蛛网膜下腔出血患者。
- 开颅时放置标准皮层脑电条,患者按随机顺序每6小时交替接受氯胺酮或其他镇静剂。
- 氯胺酮剂量根据临床效果调整,若无镇静需求则维持亚麻醉基础剂量0.1 mg/kg/hr。
- SD采用标准标准评分,对氯胺酮给药设盲。
- 临床试验注册号:NCT02501941(clinicaltrials.gov)。
主要发现
- 全部10例患者均获得成功的皮层脑电记录:8例为蛛网膜下腔出血,2例为创伤性脑损伤。
- 共获得1642小时质量合格的皮层脑电观察:停用氯胺酮833小时,使用氯胺酮809小时。
- 停用氯胺酮或剂量低于1.15 mg/kg/hr的小时与剂量≥1.15 mg/kg/hr的小时相比,SD风险增加(OR 13.838,95%CI 1.99-1000)。
- 该比值比随剂量降低而下降:1.0 mg/kg/hr(OR 4.924,95%CI 1.337-43.516)、0.85 mg/kg/hr(OR 3.323,95%CI 1.139-16.074)、0.70 mg/kg/hr(OR 2.725,95%CI 1.068-9.898),至0.55 mg/kg/hr时无效应阈值(OR 1.043,95%CI 0.565-2.135)。
- 所有氯胺酮数据合并(即任何剂量使用氯胺酮 vs 停用氯胺酮)时,使用氯胺酮期间SD减少的总体趋势未达统计学显著(χ2=3.86,p=0.42)。
临床怎么用
- 作者认为,氯胺酮在常用镇静剂量范围内有效抑制SD,即使在非插管患者中亦如此。
- 作者认为,这些数据为未来评估SD导向治疗临床改善的研究提供了基础。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Retrospective clinical data and case studies support a therapeutic effect of ketamine in suppression of spreading depolarization (SD) following brain injury. Preclinical data strongly support efficacy in terms of frequency of SD as well as recovery from electrocorticography (ECoG) depression. The authors present the results of the first prospective controlled clinical trial testing the role of ketamine used for clinical sedation on occurrence of SD. METHODS: Ten patients with severe traumatic brain injury (TBI) or aneurysmal subarachnoid hemorrhage (SAH) were recruited for this pilot trial. A standard ECoG strip was placed at the time of craniotomy, and the patients were then placed on an alternating every-6-hour schedule of ketamine or other sedation agent. The order of treatment was randomized. The ketamine dose was adjusted to clinical effect or maintained at a subanesthetic basal dose (0.1 mg/kg/hr) if no sedation was required. SD was scored using standard criteria, blinded to ketamine dosing. Occurrence of SD was compared with the hourly dose of ketamine to determine the effect of ketamine on SD occurrence. RESULTS: Successful ECoG recordings were obtained in all 10 patients: 8 with SAH and 2 with TBI. There were a total of 1642 hours of observations with adequate ECoG: 833 hours off ketamine and 809 hours on ketamine. Analysis revealed a strong dose-dependent effect such that hours off ketamine or on doses of less than 1.15 mg/kg/hr were associated with an increased risk of SD compared with hours on doses of 1.15 mg/kg/hr or more (OR 13.838, 95% CI 1.99-1000). This odds ratio decreased with lower doses of 1.0 mg/kg/hr (OR 4.924, 95% CI 1.337-43.516), 0.85 mg/kg/hr (OR 3.323, 95% CI 1.139-16.074), and 0.70 mg/kg/hr (OR 2.725, 95% CI 1.068-9.898) to a threshold of no effect at 0.55 mg/kg/hr (OR 1.043, 95% CI 0.565-2.135). When all ketamine data were pooled (i.e., on ketamine at any dose vs off ketamine), a nonsignificant overall trend toward less SD during hours on ketamine (χ2 = 3.86, p = 0.42) was observed. CONCLUSIONS: Ketamine effectively inhibits SD over a wide range of doses commonly used for sedation, even in nonintubated patients. These data also provide the first prospective evidence that the occurrence of SD can be influenced by clinical intervention and does not simply represent an unavoidable epiphenomenon after injury. These data provide the basis for future studies assessing clinical improvement with SD-directed therapy.Clinical trial registration no.: NCT02501941 (clinicaltrials.gov).
引用
- Carlson AP, Abbas M, Alunday RL, et al. Spreading depolarization in acute brain injury inhibited by ketamine: a prospective, randomized, multiple crossover trial. J Neurosurg. 2018. PMID: 29799344. doi:10.3171/2017.12.JNS171665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。